• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
LBT
Click for more information
5.56% 1.7¢

LBT INNOVATIONS LIMITED - Announcements

Market Cap $23.13M  ! watchlist Created with Sketch. Add to my watchlist

LBT Innovations Limited is a medical technology company. The Company is engaged in... LBT Innovations Limited is a medical technology company. The Company is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets and manufacture and sales of the Automated Plate Assessment System (APAS Independence). Its products include APAS Independence, APAS Analysis Modules, APAS-AMR Analysis Module, and APAS PharmaQ. The APAS Independence is a platform technology that automates culture-plate screening and interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. The APAS-AMR Analysis Module uses artificial intelligence mage analysis platform to read and interpret antimicrobial susceptibility tests (ASTs) for the detection of antimicrobial resistance (AMR). The APAS PharmaQC provides automated imaging, analysis and interpretation of microbiology culture plates used in environmental monitoring.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
LBT Long Serving Chairman Bob Finder to Retire20/07/17
LBT Appendix 3B10/07/17
LBT Appendix 4C - quarterlyPRICE SENSITIVE10/07/17
LBT Change of Director's Interest Notice10/07/17
LBT Change of Director's Interest Notice10/07/17
LBT Change of Director's Interest Notice10/07/17
LBT Change of Director's Interest Notice10/07/17
LBT Share Purchase Plan Closes07/07/17
LBT Conference Call Questions & Answers28/06/17
LBT LBT Investor Conference Call Business Update27/06/17
LBT LBT Innovations Conference Call with CEO & MD Brent Barnes26/06/17
LBT CE Mark Self Certification Finalised for APASPRICE SENSITIVE23/06/17
LBT ST VINCENTS HOSPITAL MELBOURNE TO BE FIRST APAS TRIAL SITEPRICE SENSITIVE21/06/17
LBT LBT Appointed Distributor for Australia and New ZealandPRICE SENSITIVE14/06/17
LBT LBT Appoints Artificial Intelligence Expert to the Board05/06/17
LBT Share Purchase Plan Offer Booklet01/06/17
LBT SPP Cleansing Notice31/05/17
LBT LBT Newsletter Update30/05/17
LBT Share Purchase Plan OfferPRICE SENSITIVE23/05/17
LBT Amended 2016 Annual Report08/05/17
LBT Amended 2015 Annual Report08/05/17
LBT Amended 2014 Annual Report08/05/17
LBT Amended 2013 Annual Report08/05/17
LBT Amended 2012 Annual Report08/05/17
LBT Appendix 4C - quarterlyPRICE SENSITIVE26/04/17
LBT LBT Business Update30/03/17
LBT APAS Independence Demonstration Device Ready Ahead of ECCMID30/03/17
LBT APAS INCLUDED ON THE AUSTRALIAN TGA REGISTERPRICE SENSITIVE28/03/17
LBT Appendix 3B03/03/17
LBT Half Yearly Report and AccountsPRICE SENSITIVE27/02/17
LBT LBT Business Update08/02/17
LBT LBT to Present at Melbourne Investor Forum08/02/17
LBT Appendix 3B31/01/17
LBT Appendix 4C - quarterlyPRICE SENSITIVE31/01/17
LBT Notice Under Section 708A30/01/17
LBT Change of Director's Interest Notice30/01/17
LBT Change of Director's Interest Notice30/01/17
LBT Change of Director's Interest Notice30/01/17
LBT Change of Director's Interest Notice30/01/17
LBT Appendix 3B25/01/17
LBT Results of Meeting18/01/17
LBT EGM CEO Presentation18/01/17
LBT Becoming a substantial holder21/12/16
LBT Notice of Extraordinary General Meeting/Proxy Form14/12/16
LBT Ceasing to be a substantial holder14/12/16
LBT Placement Cleansing Notice12/12/16
LBT Appendix 3B12/12/16
LBT Investor Presentation - Placement02/12/16
LBT Completion of PlacementPRICE SENSITIVE02/12/16
LBT Trading HaltPRICE SENSITIVE30/11/16
LBT Change of Director's Interest Notice - B Barnes18/11/16
LBT Appendix 3B18/11/16
LBT Change of Auditor Details18/11/16
LBT Results of Meeting16/11/16
LBT CEO Presentation - AGM 201616/11/16
LBT Chairman's Address to Shareholders16/11/16
LBT LBT Innovations Granted New Patent for United StatesPRICE SENSITIVE11/11/16
LBT Change of Director's Interest Notice-LBT.AX 27/10/16
LBT Company update-LBT.AX 27/10/16
LBT Appendix 4C - quarterly-LBT.AX PRICE SENSITIVE27/10/16
LBT Notice of initial substantial holder-LBT.AX 26/10/16
LBT Change of Director's Interest Notice-LBT.AX 21/10/16
LBT Change of Director's Interest Notice-LBT.AX 21/10/16
LBT Change of Director's Interest Notice-LBT.AX 21/10/16
LBT Change of Director's Interest Notice-LBT.AX 21/10/16
LBT Ceasing to be a substantial holder-LBT.AX 21/10/16
LBT Appendix 3B-LBT.AX 20/10/16
LBT Ceasing to be a substantial holder-LBT.AX 18/10/16
LBT Appendix 3B-LBT.AX 14/10/16
LBT Notice of Annual General Meeting/Proxy Form-LBT.AX 14/10/16
LBT Appendix 3B-LBT.AX 13/10/16
LBT Change of Director's Interest Notice-LBT.AX 12/10/16
LBT Appendix 3B-LBT.AX 11/10/16
LBT US FDA GRANTS APPROVAL FOR APAS-LBT.AX PRICE SENSITIVE10/10/16
LBT Appendix 4G-LBT.AX 28/09/16
LBT Annual Report to shareholders-LBT.AX 28/09/16
LBT LBT to Present at AusBiotech Broker Meets Biotech Event-LBT.AX 22/09/16
LBT Preliminary Final Report-LBT.AX PRICE SENSITIVE31/08/16
LBT Initial Director's Interest Notice-LBT.AX 09/08/16
LBT Final Director's Interest Notice-LBT.AX 09/08/16
LBT Appendix 4C - quarterly-LBT.AX PRICE SENSITIVE29/07/16
LBT Retiring LBT CEO Lusia Guthrie Appointed Chair of CCS AG-LBT.AX 10/06/16
LBT LBT granted patent in Japan for core APAS technology-LBT.AX PRICE SENSITIVE19/05/16
LBT Cochlear Executive Brent Barnes Appointed CEO of LBT-LBT.AX PRICE SENSITIVE09/05/16
LBT Appendix 3B-LBT.AX 09/05/16
LBT Appendix 4C - quarterly-LBT.AX PRICE SENSITIVE26/04/16
LBT LBT Receives Notice of Allowance for Third Patent-LBT.AX PRICE SENSITIVE07/04/16
LBT Change of Director's Interest Notice11/03/16
LBT Half Yearly Report and AccountsPRICE SENSITIVE29/02/16
LBT Appendix 4C - quarterlyPRICE SENSITIVE29/01/16
LBT LBT Innovations Completes U.S. Regulatory SubmissionPRICE SENSITIVE22/12/15
LBT LBT Concludes APAS Clinical Trial ProgramPRICE SENSITIVE16/11/15
LBT Appendix 3B09/11/15
LBT Results of Meeting21/10/15
LBT AGM 2015 CEO Presentation21/10/15
LBT Chairman's Address to Shareholders21/10/15
LBT Appendix 4C - quarterlyPRICE SENSITIVE20/10/15
LBT LBT Receives Notice of Allowance for Second PatentPRICE SENSITIVE14/10/15
LBT LBT CEO RetirementPRICE SENSITIVE12/10/15
LBT APAS Exceeds Expectations in Key U.S. Clinical TrialsPRICE SENSITIVE07/10/15
LBT Long Serving Chairman Bob Finder to Retire
20/07/17
LBT Appendix 3B
10/07/17
LBT Appendix 4C - quarterly
10/07/17PRICE SENSITIVE
LBT Change of Director's Interest Notice
10/07/17
LBT Change of Director's Interest Notice
10/07/17
LBT Change of Director's Interest Notice
10/07/17
LBT Change of Director's Interest Notice
10/07/17
LBT Share Purchase Plan Closes
07/07/17
LBT Conference Call Questions & Answers
28/06/17
LBT LBT Investor Conference Call Business Update
27/06/17
LBT LBT Innovations Conference Call with CEO & MD Brent Barnes
26/06/17
LBT CE Mark Self Certification Finalised for APAS
23/06/17PRICE SENSITIVE
LBT ST VINCENTS HOSPITAL MELBOURNE TO BE FIRST APAS TRIAL SITE
21/06/17PRICE SENSITIVE
LBT LBT Appointed Distributor for Australia and New Zealand
14/06/17PRICE SENSITIVE
LBT LBT Appoints Artificial Intelligence Expert to the Board
05/06/17
LBT Share Purchase Plan Offer Booklet
01/06/17
LBT SPP Cleansing Notice
31/05/17
LBT LBT Newsletter Update
30/05/17
LBT Share Purchase Plan Offer
23/05/17PRICE SENSITIVE
LBT Amended 2016 Annual Report
08/05/17
LBT Amended 2015 Annual Report
08/05/17
LBT Amended 2014 Annual Report
08/05/17
LBT Amended 2013 Annual Report
08/05/17
LBT Amended 2012 Annual Report
08/05/17
LBT Appendix 4C - quarterly
26/04/17PRICE SENSITIVE
LBT LBT Business Update
30/03/17
LBT APAS Independence Demonstration Device Ready Ahead of ECCMID
30/03/17
LBT APAS INCLUDED ON THE AUSTRALIAN TGA REGISTER
28/03/17PRICE SENSITIVE
LBT Appendix 3B
03/03/17
LBT Half Yearly Report and Accounts
27/02/17PRICE SENSITIVE
LBT LBT Business Update
08/02/17
LBT LBT to Present at Melbourne Investor Forum
08/02/17
LBT Appendix 3B
31/01/17
LBT Appendix 4C - quarterly
31/01/17PRICE SENSITIVE
LBT Notice Under Section 708A
30/01/17
LBT Change of Director's Interest Notice
30/01/17
LBT Change of Director's Interest Notice
30/01/17
LBT Change of Director's Interest Notice
30/01/17
LBT Change of Director's Interest Notice
30/01/17
LBT Appendix 3B
25/01/17
LBT Results of Meeting
18/01/17
LBT EGM CEO Presentation
18/01/17
LBT Becoming a substantial holder
21/12/16
LBT Notice of Extraordinary General Meeting/Proxy Form
14/12/16
LBT Ceasing to be a substantial holder
14/12/16
LBT Placement Cleansing Notice
12/12/16
LBT Appendix 3B
12/12/16
LBT Investor Presentation - Placement
02/12/16
LBT Completion of Placement
02/12/16PRICE SENSITIVE
LBT Trading Halt
30/11/16PRICE SENSITIVE
LBT Change of Director's Interest Notice - B Barnes
18/11/16
LBT Appendix 3B
18/11/16
LBT Change of Auditor Details
18/11/16
LBT Results of Meeting
16/11/16
LBT CEO Presentation - AGM 2016
16/11/16
LBT Chairman's Address to Shareholders
16/11/16
LBT LBT Innovations Granted New Patent for United States
11/11/16PRICE SENSITIVE
LBT Change of Director's Interest Notice-LBT.AX
27/10/16
LBT Company update-LBT.AX
27/10/16
LBT Appendix 4C - quarterly-LBT.AX
27/10/16PRICE SENSITIVE
LBT Notice of initial substantial holder-LBT.AX
26/10/16
LBT Change of Director's Interest Notice-LBT.AX
21/10/16
LBT Change of Director's Interest Notice-LBT.AX
21/10/16
LBT Change of Director's Interest Notice-LBT.AX
21/10/16
LBT Change of Director's Interest Notice-LBT.AX
21/10/16
LBT Ceasing to be a substantial holder-LBT.AX
21/10/16
LBT Appendix 3B-LBT.AX
20/10/16
LBT Ceasing to be a substantial holder-LBT.AX
18/10/16
LBT Appendix 3B-LBT.AX
14/10/16
LBT Notice of Annual General Meeting/Proxy Form-LBT.AX
14/10/16
LBT Appendix 3B-LBT.AX
13/10/16
LBT Change of Director's Interest Notice-LBT.AX
12/10/16
LBT Appendix 3B-LBT.AX
11/10/16
LBT US FDA GRANTS APPROVAL FOR APAS-LBT.AX
10/10/16PRICE SENSITIVE
LBT Appendix 4G-LBT.AX
28/09/16
LBT Annual Report to shareholders-LBT.AX
28/09/16
LBT LBT to Present at AusBiotech Broker Meets Biotech Event-LBT.AX
22/09/16
LBT Preliminary Final Report-LBT.AX
31/08/16PRICE SENSITIVE
LBT Initial Director's Interest Notice-LBT.AX
09/08/16
LBT Final Director's Interest Notice-LBT.AX
09/08/16
LBT Appendix 4C - quarterly-LBT.AX
29/07/16PRICE SENSITIVE
LBT Retiring LBT CEO Lusia Guthrie Appointed Chair of CCS AG-LBT.AX
10/06/16
LBT LBT granted patent in Japan for core APAS technology-LBT.AX
19/05/16PRICE SENSITIVE
LBT Cochlear Executive Brent Barnes Appointed CEO of LBT-LBT.AX
09/05/16PRICE SENSITIVE
LBT Appendix 3B-LBT.AX
09/05/16
LBT Appendix 4C - quarterly-LBT.AX
26/04/16PRICE SENSITIVE
LBT LBT Receives Notice of Allowance for Third Patent-LBT.AX
07/04/16PRICE SENSITIVE
LBT Change of Director's Interest Notice
11/03/16
LBT Half Yearly Report and Accounts
29/02/16PRICE SENSITIVE
LBT Appendix 4C - quarterly
29/01/16PRICE SENSITIVE
LBT LBT Innovations Completes U.S. Regulatory Submission
22/12/15PRICE SENSITIVE
LBT LBT Concludes APAS Clinical Trial Program
16/11/15PRICE SENSITIVE
LBT Appendix 3B
09/11/15
LBT Results of Meeting
21/10/15
LBT AGM 2015 CEO Presentation
21/10/15
LBT Chairman's Address to Shareholders
21/10/15
LBT Appendix 4C - quarterly
20/10/15PRICE SENSITIVE
LBT LBT Receives Notice of Allowance for Second Patent
14/10/15PRICE SENSITIVE
LBT LBT CEO Retirement
12/10/15PRICE SENSITIVE
LBT APAS Exceeds Expectations in Key U.S. Clinical Trials
07/10/15PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
1.7¢ 		Change
-0.001(5.56%) 		Mkt cap ! $23.13M
Open High Low Value Volume
1.8¢ 1.8¢ 1.7¢ $13.20K 747.0K

Buyers (Bids)

No. Vol. Price($)
4 776749 1.7¢
 

Sellers (Offers)

Price($) Vol. No.
1.8¢ 238095 1
View Market Depth
Last trade - 16.10pm 26/11/2024 (20 minute delay) ?
LBT (ASX) Chart

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Chaos reigns markets – so let's take stock of where we're at ahead of December For many people, it feels like the world has been getting crazier each year since 2020 (or 2016.) It's likely to continue
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.